Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

New Gilead Sciences (GILD) HIV Concerns 'Overdone' - RBC

October 31, 2018 12:24 PM EDT

RBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) amid new debates about the long-term longevity of their core HIV franchise in the face of generics and potential competition.

Abrahams said the concerns are 'substantially overdone'. Further, he said... More